NCT06477536

Long-Term Safety and Efficacy of HB0034 in Subjects With Generalized Pustular Psoriasis

A Phase IIb, Long-Term Extension Study to Evaluate the Safety and Efficacy of HB0034 in the Treatment of Adult Subjects With Generalized Pustular Psoriasis

• Status: Recruiting
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 33 (estimated)
• Sponsor: Shanghai Huaota Biopharmaceutical Co., Ltd. · Industry
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase IIb, long term extension study to evaluate the safety and efficacy of HB0034 in adult subjects with generalized pustular psoriasis (GPP).

Detailed description

This study will also evaluate the pharmacokinetic (PK) profile of HB0034 and explore the immunogenicity of HB0034 in subjects with GPP

Conditions

• Generalized Pustular Psoriasis

Interventions

Type	Name	Description
DRUG	HB0034	300mg, i.v. Q4W

Timeline

• Start date: 2024-09-02
• Primary completion: 2025-12-30
• Completion: 2026-06-30
• First posted: 2024-06-27
• Last updated: 2025-02-14

Locations

3 sites across 1 country: China